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Available online 26 August 2016Previous research suggests a genetic overlap between nonsyndromic cleft lipwith orwithout cleft palate (NSCL/P)
and cancer. The aim of the present study was to identify common genetic risk loci for NSCL/P and cancer entities
that have been reported to co-occur with orofacial clefting. This was achieved through the investigation of large
genome-wide association study datasets. Investigations of 12 NSCL/P single nucleotide polymorphisms (SNPs)
in 32 cancer datasets, and 204 cancer SNPs in two NSCL/P datasets, were performed. The SNPs rs13041247
(20q12) and rs6457327 (6p21.33) showed suggestive evidence for an association with both NSCL/P and a speciﬁc
cancer entity. These loci harbor genes of biological relevance to oncogenesis (MAFB and OCT4, respectively). This
study is the ﬁrst to characterize possible pleiotropic risk loci for NSCL/P and cancer in a systematic manner. The
data represent a starting point for future research by identifying a genetic link between NSCL/P and cancer.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Orofacial clefting (OFC) is a common congenital malformation com-
prising several subtypes. Themost frequent form is nonsyndromic ‘cleft
lip with or without cleft palate’ (NSCL/P), which is characterized by
clefting of the upper lip and facultative clefting of the palate [46].
NSCL/P etiology involves both environmental and genetic factors.
Genome-wide association studies (GWAS) have provided insights into
the genetic background of NSCL/P through the identiﬁcation of several
risk loci [40,42].
Research suggests a common genetic etiology for congenital
malformations - including OFC - and speciﬁc cancer entities. Miller
[45] analyzed the death certiﬁcates of approximately 30,000 pediatric.
en access article under the CC BY-NCcancer cases in order to determine the prevalence of co-morbid congen-
ital abnormalities. Miller reported associations between Down's
syndrome and leukemia, and aniridia andWilms' tumor. Various epide-
miological study designs have since been applied to identify associa-
tions between speciﬁc cancer entities and OFC or particular clefting
subtypes. One of the largest investigations to date is the Danish registry
cohort study of Bille et al. [4]. The authors found a signiﬁcantly higher
prevalence of: breast cancer in females with cleft lip and/or cleft palate;
brain cancer in females with cleft palate; and lung cancer in males with
cleft lip and palate. Further studies have supported an association [13,
43,47,72], whereas others have not [6,8,56].
As both cancer and OFC have a multifactorial etiology, shared risk
factors might be genetic, environmental, or a combination of both.
Molecular studies - in particular recent GWAS - have identiﬁed suscep-
tibility factors for various cancer subtypes [14]. The ﬁrst GWAS of cancer
in the late 2000s reported a limited number of loci for themost common-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
NSCL/P-associated risk SNPs identiﬁed in GWAS.
SNP-ID Allele⁎ Chr. region Position (Mb) Reference
rs560426 G-A 1p22.1 94.32–94.35 [2]
rs861020 A-G 1q32.2 208.00–208.12 [2]
rs742071 T-G 1p36 18.85 [40]
rs7590268 G-T 2p21 43.39 [40]
rs7632427 C-T 3p11.1 89.61 [40]
rs12543318 C-A 8q21.3 88.93 [40]
rs987525 A-C 8q24.21 129.77–130.30 [5]
rs7078160 A-G 10q25 118.81–118.83 [41]
rs8001641 A-G 13q31 79.57–79.60 [40]
rs1873147 C-T 15q22 61.09 [40]
rs227731 C-A 17q22 52.12 [41]
rs13041247 C-T 20q12 38.70–38.71 [2]
Chr. = chromosomal.
⁎ Minor allele ﬁrst, risk allele for NSCL/P in bold.
23E. Dunkhase et al. / Genomics Data 10 (2016) 22–29malignancies. To date, individual studies and meta-analyses have iden-
tiﬁed approximately 50 susceptibility loci for colorectal cancer, N70 for
breast cancer, and N100 for prostate cancer. Of particular interest is
the ﬁnding that chromosomal region 8q24.21 contains several cancer-
risk single nucleotide polymorphisms (SNPs) [25], and a major risk
locus for NSCL/P [5].
The majority of published investigations into a common genetic eti-
ology for OFC and cancer have been purely descriptive. To date, strong
molecular evidence for an association between cancer and OFC has
been generated for only one gene. In the respective resequencing
study, a causative role for the gene CDH1was identiﬁed in both gastric
cancer and OFC [9]. A limitation of previous studies is that they were
based on the analysis of candidate genes and/or particular pedigrees.
To overcome this, the present study used genome-wide SNP data from
large cohorts of patients with sporadic cancers or NSCL/P. Analyses
were performed to identify common genetic risk loci for NSCL/P and
those cancer entities for which co-occurrence with NSCL/P has been re-
ported. The identiﬁcation of shared risk loci would provide insights into
common underlying mechanisms.
2. Materials and methods
2.1. Cancer entity search strategy
In a ﬁrst step, a Pubmed search was performed to locate original
studies published prior to July 2012 that had investigated an association
between OFC and cancer. The following search terms were used: “cleft
cancer”, “cleft tumor”, “cleft lip cancer”, “cleft lip tumor”, “cleft palate
cancer”, “cleft palate tumor”, “facial cleft cancer”, “facial cleft tumor”,
“oral cleft cancer”, “oral cleft tumor”, “orofacial cleft cancer”, and
“orofacial cleft tumor”. In the OFC literature, nomenclature is applied in-
consistently, and these broad search termswere used in order to ensure
that relevant studies were not overlooked due to the use of alternative
morphological classiﬁcation. The reference lists of these publications
were then scrutinized to identify additional studies. On the basis of
these search results, a list of cancer entities with a reported association
with any form of OFC was compiled.
This list was then reduced to cancer entities with a reported associ-
ation with NSCL/P. Studies that had investigated other OFC phenotypes
(i.e., cleft palate only, syndromic OFC, or anomalies such as tooth
agenesis and biﬁd uvula) were excluded. Data from case reports and
animal models were also excluded from the analyses (Supplementary
Table S1).
2.2. Cancer GWAS search strategy
In a second step, a search of the “NHGRI GWASOnline Catalog” ([29],
http://www.genome.gov/gwastudies)was performed to identify GWAS
of those cancer entities for which an association with NSCL/P had
been reported (cancer entities of interest listed in Supplementary
Table S1). Since this GWAS catalog is not exhaustive, the search was
complemented using PubMed. The following search terms, followed
by the respective cancer subtype, were used: “genome-wide association
studies”, “genome-wide association study”, “gwas”, “gwa”.
2.3. Identiﬁcation of NSCL/P risk SNPs from the literature
Prior to July 2012, three GWAS of NSCL/P were performed in
European case-control samples [5,26,41], and one GWAS was per-
formed in European and Asian trios [2]. Subsequently, two meta-
analyses of GWAS data from Mangold et al. [41] and Beaty et al. [2]
were performed [40]. In total, 12 loci in these studies showed
genome-wide signiﬁcance. These comprised one established NSCL/P
risk locus (IRF6), and 11 novel loci. Twelve lead SNPs at these loci
were chosen as NSCL/P risk SNPs for the present study (Table 1).2.4. Identiﬁcation of cancer risk SNPs from the literature
All autosomal SNPs with genome-wide signiﬁcance in at least one
cancer GWAS published prior to July 2012 were listed. According to
the guidelines of the International HapMap Consortium [32], an SNP
should be considered genome-wide signiﬁcant if it achieves a P-value
below a threshold of 5 × 10−8. As an exception to this rule, the present
study also included SNPs with a P-value of N5 × 10−8 if they had been
deﬁned as genome-wide signiﬁcant in the original study.
2.5. Exploration of genome-wide SNP datasets
Data on NSCL/P-associated genetic variants were retrieved from the
meta-analyses of the two largest GWAS of NSCL/P to date [40]. Ludwig
et al. [40] included 497,084 SNPs, which had been genotyped in 666
complete European trios, 795 complete Asian trios, and 399 patients
and 1318 controls of Central European origin. This study included 95%
of all individuals available at that time with both NSCL/P and genome-
wide data. For SNPs in the cancer SNP list, analyses were performed
to determine association with NSCL/P in the two meta-analyses:
i) European (meta_Euro); and ii) the combined European/Asian popula-
tion (meta_all) datasets.
Additionally, the corresponding authors of all cancer GWAS used for
SNP selection were contacted. These researchers were asked to retrieve
association information from their cancer GWAS datasets for each lead
SNP from the 12 NSCL/P risk loci (Table 1).
For both analyses, cancer and NSCL/P SNPs that were not represent-
ed in the respective analyzed data were replaced by a proxy SNP
(r2 N 0.5 in the HapMap CEU population, Supplementary methods).
For the P-values of cancer-associated SNPs in the NSCL/P meta-
analyses, correction for multiple testing was performed using a simula-
tion procedure. This was based on 10,000 replicated samples, and in-
volved permutation of: (i) the case and control status of individuals;
and (ii) the transmitted and non-transmitted parental alleles.
For the analysis of NSCL/P-associated SNPs in the cancer GWAS,
a correction factor of 384 was used (12 risk loci, 32 cancer GWAS
datasets).
3. Results
The cancer entity search for studies that had analyzed the co-
occurrence of orofacial anomalies and cancer identiﬁed 36 publications
(Supplementary Table S1). Of these, 10 contained sufﬁcient information
to deduce that the described associations were with the NSCL/P pheno-
type. These 10 studies covered 11 different cancer entities, all of which
were primary forms of cancer, i.e., they were not metastatic tumors.
These cancer entities comprised: brain cancer [4,22,43]; breast cancer
[4,43]; colorectal cancer [43]; leukemia [43,44,48,69,72]; liver cancer
Table 2
Cancer-associated SNPs with nominal signiﬁcance in NSCL/P.
SNP Risk allele cancera Risk allele NSCL/Pb Proxy needed? Chr. region Pmeta_Euro Pmeta_all Associated cancer entity Reference
rs6457327 C C NO 6p21.33 1.92 × 10−4 4.18 × 10−3 Lymphoma (FL) [54]
rs17505102 G G rs16864725 3q28 1.93 × 10−3 2.82 × 10−2 Leukemia (ALL) [20]
rs3131379 n/s A NO 6p21.33 4.29 × 10−3 5.69 × 10−3 Lung cancer [65]
rs3117582 C C NO 6p21.33 4.74 × 10−3 5.46 × 10−3 Lung cancer [65]
rs4779584 n/s C NO 15q13 8.76 × 10−3 7.76 × 10−2 Colorectal cancer [49]
rs10934853 A A NO 3q21.3 1.99 × 10−2 1.13 × 10−3 Prostate cancer [27]
rs6712055 C T NO 2q35 2.29 × 10−2 1.05 × 10−1 Neuroblastoma [10]
rs17728461 G C rs9614158 22q12.2 2.51 × 10−2 1.90 × 10−1 Lung cancer [31]
rs4857841 A A NO 3q21.3 2.56 × 10−2 1.22 × 10−3 Prostate cancer [27]
rs204999 A A NO 6p21.32 2.72 × 10−2 2.25 × 10−1 Lymphoma (cHL) [15]
rs11170164 A G rs11170148 12q13.13 3.94 × 10−2 3.94 × 10−2 Skin cancer (BCC) [55]
rs2055109 C T NO 3p11.2 4.24 × 10−2 4.07 × 10−2 Prostate cancer [1]
rs1321311 A A NO 6p21.2 4.28 × 10−2 6.41 × 10−2 Colorectal cancer [17]
rs10995190 G A NO 10q21.2 4.47 × 10−2 4.76 × 10−2 Breast cancer [63]
rs4635969 C C NO 5p15.33 9.66 × 10−2 3.35 × 10−2 Lung cancer [35]
rs17021918 C T NO 4q22.3 1.24 × 10−1 1.74 × 10−2 Prostate cancer [19]
rs1862748 C T NO 16q22.1 1.50 × 10−1 3.57 × 10−2 Colorectal cancer [30]
n/s = not speciﬁed; Pmeta_Euro and Pmeta_all = P-value from Likelihood ratio test in the European or European/Asian meta-analysis respectively; FL = follicular lymphoma; ALL = acute
lymphoblastic leukemia; cHL = classical Hodgkin lymphoma; BCC = basal cell carcinoma.
a Risk allele in cancer GWAS.
b Risk allele in NSCL/P GWAS (in identical strand orientation).
24 E. Dunkhase et al. / Genomics Data 10 (2016) 22–29[43]; lung cancer [4,43]; lymphoma [72]; neuroblastoma [47]; prostate
cancer [43]; retinoblastoma [7]; and skin cancer [43]. The remaining
26 studies did not meet the present inclusion criteria.
Convincing GWAS results were found for nine of the 11 cancer enti-
ties. For retinoblastoma, no GWASwas found and this cancer entity was
therefore excluded. The single GWAS of liver cancer had identiﬁed sus-
ceptibility variants for hepatitis B and C virus-induced hepatocellular
carcinoma only [11,34,36,53,70]. Given the virus-related origin of liver
cancer in these GWAS, this cancer entity was excluded from further
analysis. For the remaining nine cancer entities, 233 SNPswere reported
to show genome-wide signiﬁcance (Supplementary Tables S2.1-S2.9).
Most of these SNPs had been identiﬁed in GWAS of prostate cancerTable 3
NSCL/P associated SNPs with nominal signiﬁcance in cancer GWAS.
SNP-ID (risk allele in NSCL/P) Proxy required? Cancer entity Risk R
rs13041247 (T) *† NO skin cancer (SCC) C T
rs13041247 (T) *† NO skin cancer (BCC) C T
rs13041247 (T) *† NO skin cancer (CM) T C
rs13041247 (T) † NO lymphoma (CLL) T C
rs13041247 (T) *† NO lymphoma (CLL) T C
rs13041247 (T) * NO brain cancer (glioma) T C
rs1873147 (C) * NO brain cancer (glioma) A G
rs227731 (C) *† NO prostate cancer T G
rs227731 (C) *† NO skin cancer (BCC) T G
rs227731 (C) *† NO skin cancer (CM) T G
rs227731 (C) * NO skin cancer (BCC) T G
rs560426 (G) * NO prostate cancer T C
rs560426 (G) *† NO colorectal cancer C T
rs560426 (G) * NO lymphoma (DLBCL) C T
rs7078160 (A) *† NO skin cancer (BCC) G A
rs7078160 (A) * NO brain cancer (glioma) A G
rs7078160 (A) *† NO skin cancer (CM) G A
rs7632427 (T) * NO skin cancer (SCC) C T
rs7632427 (T) † NO brain cancer (glioma) T C
rs861020 (A) ‡ rs1962735 leukemia (ALL) G A
rs861020 (A) * NO lymphoma (FL) G A
rs987525 (A) * NO brain cancer (glioma) A C
rs987525 (A) * NO brain cancer (glioma) A C
Risk = Risk allele in cancer GWAS; Ref = Reference allele in cancer GWAS; OR = Odds Rat
carcinoma; BCC = basal cell carcinoma; CM= cutaneous melanoma; CLL = chronic lymphoc
European ethnicity; AS = Asian ethnicity; n/s = not speciﬁed.
a Association P-value from cancer GWAS.
b 99% are known or assumed to be White and Not Hispanic.
c German subgroup.
d US subgroup.
e French subgroup.(n= 57). Only eight SNPs were derived from three GWAS of brain can-
cer (glioma). Sixty-six of the 233 SNPs required replacement by a proxy
SNP for further analysis, and nine variantswere excluded due to the lack
of a proxy SNP (for details see Supplementary Tables S2.1-S2.9). In total,
204 cancer-associated SNPs were analyzed in the NSCL/P meta-analysis
data.
Nominal signiﬁcance (P b 0.05) was achieved for a total of 17 cancer
SNPs: 14 cancer SNPs in the meta_Euro subsample; and 12 cancer SNPs
in the meta_All subsample (Table 2). In both instances, this is more
than would have been expected by chance (expected number per
subsample: 10.2). For 15 of the 17 nominally signiﬁcant cancer SNPs,
the “cancer risk allele” was reported in the literature. For eight ofef P-valuea OR OR type Number of cases/controls Sample ethnicity
4.73 × 10−6 1.23 allelic 973/N60,000 EU
1.04 × 10−3 1.10 allelic 2807/N60,000 EU
3.54 × 10−3 1.16 allelic 725/N60,000 EU
3.31 × 10−2 1.27 genotypic 407/296 EUb
4.14 × 10−2 1.25 allelic 148/N60,000 EU
4.18 × 10−2 1.14 n/s 846/1310 EUc
4.50 × 10−2 1.17 n/s 846/1310 EUc
1.40 × 10−3 1.10 allelic 2682/N60,000 EU
2.35 × 10−3 1.09 allelic 2807/N60,000 EU
1.83 × 10−2 1.14 allelic 725/N60,000 EU
3.29 × 10−2 1.08 allelic 2045/6013 EU
5.83 × 10−4 1.19 n/s 1583/4944 AS
1.85 × 10−3 1.06 allelic 12,620/15,110 EU
4.23 × 10−2 1.23 allelic 256/747 EU
1.62 × 10−3 1.14 allelic 2807/N60,000 EU
3.12 × 10−2 1.16 n/s 1247/2236 EUd
3.15 × 10−2 1.16 allelic 725/N60,000 EU
1.46 × 10−2 1.12 allelic 973/N60,000 EU
4.84 × 10−2 1.10 additive 2331/3077 AS
3.13 × 10−2 1.28 n/s 1696/3535 EU
4.97 × 10−2 1.33 allelic 213/750 EU
1.15 × 10−2 1.20 n/s 846/1310 EUc
3.65 × 10−2 1.14 n/s 1423/1190 EUe
io; * SNP genotyped; † SNP imputed; ‡ no data available for SNP; SCC = squamous cell
ytic leukemia; DLBCL = Diffuse large B-cell lymphoma; FL = follicular lymphoma; EU =
Table 4
Cancer risk SNPs at 8q24.21 and distance from NSCL/P risk SNP rs987525.
Cancer entity SNP-ID Risk allelea ORb Position Distance from rs987525 (kb) Reference
Breast cancer rs13281615 C 1.08 128,424,800 −1591 [18]
Colorectal cancer rs6983267 G 1.21 128,476,625 −1539 [62]
Colorectal cancer rs10505477 n/s 1.12 128,482,487 −1533 [62]
Colorectal cancer rs7014346 A 1.19 128,493,974 −1521 [60]
Glioma rs4295627 G 1.36 130,754,639 739 [52]
Lymphoma (cHL) rs2608053 G 1.20 129,261,453 −754 [21]
Lymphoma (cHL) rs2019960 G 1.33 129,145,014 −870 [21]
Lymphoma (CLL) rs2456449 G 1.26 128,262,163 −1753 [16]
Lymphoma (CLL) rs2466024 A 1.20 128,257,201 −1758 [16]
Prostate cancer rs1447295 A 1.60 128,554,220 −1461 [28]
Prostate cancer rs16901979 A 1.79 128,194,098 −1821 [28]
Prostate cancer rs6983267 G 1.27 128,482,487 −1533 [68]
Prostate cancer rs7837688 T 1.47 128,608,542 −1407 [68]
Prostate cancer rs4242382 A n/s 128,586,755 −1429 [61]
Prostate cancer rs16902094 G 1.21 128,389,528 −1626 [27]
Prostate cancer rs445114 T 1.14 128,410,090 −1605 [27]
Prostate cancer rs16902104 T 1.21 128,392,363 −1623 [27]
n/s = not speciﬁed; cHL = classical Hodgkin's lymphoma; CLL = chronic lymphocytic leukemia.
a Risk allele in cancer GWAS.
b Allelic odds ratio in cancer GWAS.
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allele” (Table 2). For the cancer-associated SNP rs6457327 on chromo-
some 6p21.33, a borderline association was reported in the European
NSCL/P dataset. However, this became non-signiﬁcant following correc-
tion for multiple testing (Padj = 0.0528). In the original report, the SNP
rs6457327was associatedwith follicular lymphoma [54]. In the original
cancer GWAS, risk was conferred by the C allele at this SNP, which is
identical to the risk allele in the NSCL/P meta-analyses datasets.
Analyses were then performed to identify associations with the lead
SNPs of the 12 NSCL/P loci in 32 different cancer sample datasets. Eight
SNPs achieved nominal signiﬁcance in at least one sample dataset. The
association of rs13041247 at chromosome 20q12 with squamous cell
cancer of the skin (Padj = 4.73 × 10−6 × 384 = 0.0018, data extracted
from the Icelandic Cancer Registry) remained signiﬁcant after conserva-
tive Bonferroni correction for 384 tests. However, the risk allele for this
SNP reported in squamous cell cancer of the skin differs from that found
in the NSCL/P patients (Table 3).
Two CDH1 SNPs (rs9929218 and rs1862748) were included in the
present study as they had shown genome-wide signiﬁcant results in a
GWAS of colorectal cancer [30]. The SNP rs1862748 showed nominal
signiﬁcance (P= 3.57 × 10−2) in the present NSCL/P dataset (Table 2).
The literature search for cancer risk SNPs identiﬁed 16 SNPs in the
region of 8q24.21. This region also contains a key susceptibility locus
for NSCL/P, with the top marker being rs987525. None of the cancer
risk SNPs showed signiﬁcant association in the NSCL/P datasets, and
no association with rs987525 was found in any of the investigated can-
cer datasets (Table 4).
4. Discussion
The aim of the present study was to identify common genetic risk
loci for NSCL/P and those cancer entities that have been reported to
co-occur with NSCL/P in descriptive studies. Two approaches were
used. First, conclusively identiﬁed cancer susceptibility variants were
analyzed in a large genome-wide SNP dataset of NSCL/P patients.
Second, knownNSCL/P risk lociwere analyzed inGWAS data for speciﬁc
cancer entities. Analysis of only a subset of candidate SNPs, i.e., those
identiﬁed as being genome-wide signiﬁcant for one trait, reduced the
number of tests and thus the requirement for correction, thereby in-
creasing the chances of identifying common risk loci.
In principle, an overlapping genetic contribution to both traits could
also be quantiﬁed using a genome wide polygenic score approach [51].
However, for this etiological overlap to be apparent in a polygenic score,
a speciﬁc cancer entity and NSCL/P would have to share a large numberof genetic risk factors. Given the weak associations reported for cancer
entities and NSCL/P in previous epidemiological studies, the presence
of a large number of shared genetic risk factors cannot be assumed. In
addition, since the polygenic score allows no conclusions to be drawn
concerning a particular gene, this approach would allow no conclusions
concerning a common biological pathway for NSCL/P and any speciﬁc
cancer entity. We therefore considered the present methodology to be
the more appropriate approach to our research question.
One associationwithstood correction for multiple testing. The NSCL/
P-associated risk SNP rs13041247 at chromosome 20q12 showed
genome-wide signiﬁcant association in the dataset of the Icelandic
cancer registry for squamous cell carcinoma of the skin. However, the
NSCL/P risk allele (T) is not identical to the skin cancer risk allele (C).
The SNP rs13041247 maps 45 kb downstream of the musculoaponeu-
rotic ﬁbrosarcoma oncogene homolog B (MAFB) gene, which encodes
the v-maf transcription factor. In the GWAS of NSCL/P conducted by
Beaty et al. [2], whichwas the ﬁrst to describe association of this variant
with NSCL/P, sequencing of conserved elements within the 3′ region
and the coding region of MAFB in NSCL/P cases and controls from
Iowa and the Philippines revealed an overrepresentation of a rare mis-
sense variant (His131Gln). The contribution of this variant to NSCL/P
awaits elucidation [2]. Animal studies have provided additional support
for the hypothesis thatMAFB is a candidate gene for NSCL/P at this locus
by showing that its homolog in rodents is expressed in craniofacial
structures during embryogenesis [2]. Recently, Lopez-Pajares et al.
[39] demonstrated that MAF and MAFB control the expression of the
transcription factor genes GRHL3, ZNF750, PRDM1, and KLF4. Together,
these genes form a network that is essential for epidermal differentia-
tion. Previous studies have demonstrated that the grainyhead-like tran-
scription factor 3 gene GRHL3 causes the autosomal dominant Van der
Woude syndrome [50], which is the most common syndromic form of
cleft lip and palate. Furthermore, Bhandari et al. [3] observed a marked
reduction or absence of GRHL3 expression in squamous cell skin carci-
noma samples from mice and humans. A recent study identiﬁed domi-
nant negative KLF4 variants in patients with NSCL/P [38].
Of the cancer associated SNPs, the most signiﬁcant P-value in the
NSCL/P meta-analyses datasets was found for rs6457327 at 6p21.33, al-
though this fell short of signiﬁcance after correction formultiple testing.
This SNP was originally reported by Skibola et al. [54] as a risk locus for
follicular lymphoma, and maps 58 kb downstream of the POU class 5
homeobox 1 (POU5F1) gene, also known as OCT4. This gene encodes a
transcription factor with an important role in embryonic development,
in particular during early embryogenesis, and which is necessary for
maintaining embryonic stem cell pluripotency [57]. Wang et al. [66]
26 E. Dunkhase et al. / Genomics Data 10 (2016) 22–29showed that OCT4 regulates and interacts with the BMP4 pathway
in specifying different developmental fates in human embryonic
stem cells. Notably, the BMP4 pathway is involved in mammalian
palatogenesis [71], and mutations in BMP4 have been associated
with human NSCL/P [12,58,59]. Research has shown that OCT4 is
overexpressed in cancer cell lines and in diverse cancer entities
[24,37,67], suggesting that aberrant transcriptional regulation of OCT4
might be a mechanism in cancer susceptibility. Thus, a plausible
hypothesis is that rs6457327 regulates OCT4 expression, and that this
regulation is a possible common process in oncogenesis and the devel-
opment of NSCL/P.
An important consideration in interpreting the present results is that
the publication search adhered to very strict inclusion criteria, which
might have introduced two sources of bias. First, we concentrated on
investigating cancer risk associationwith NSCL/P and no other OFC sub-
type in order to reduce any existing genetic heterogeneity. However, as
OFC nomenclature is applied inconsistently, we cannot exclude the pos-
sibility that our investigation included cancer entities that were associ-
ated with forms of OFC other than “pure” NSCL/P. Second, we may have
rejected genuinely associated cancer entities due to a non-precise
description of a possible association with NSCL/P in the respective
publication. Frebourg et al. [23] and Kluijt et al. [33] described a possible
co-segregation of OFC and CDH1-related gastric cancer, and recent
resequencing and association studies strongly support a contribution
to NSCL/P of predominantly rare and moderately penetrant CDH1 vari-
ants [9]. As this co-occurrence was not precisely related to NSCL/P in
the initial studies, andno other study of this cancer entity had been pub-
lished by July 2012, gastric cancer was not included in the present can-
cer entity list. Nonetheless, two CDH1 SNPs (rs9929218 and rs1862748)
were included, as they had shown genome-wide signiﬁcant results in a
GWAS of colorectal cancer [30], and rs1862748 showed nominal signif-
icance (P= 3.57 × 10−2) in the present NSCL/P dataset (Table 2).
Another important consideration is that most of the individuals
investigated in the descriptive studies had a relatively low mean- and
median age. Bille et al. [4] were the only authors to investigate the co-
occurrence of OFC and cancer in adults (maximum age: 62 years). Con-
sequently, the present analysesmay have failed to consider cancers that
are more frequent in later life.
In addition, we cannot exclude the possibility that NSCL/P is associ-
ated with cancer-subtypes other than those considered in the present
study. Many of the GWAS concentrated on speciﬁc cancer subtypes.
For example, studies of leukemia and lymphoma were conducted
using case cohorts of acute lymphoblastic leukemia, chronic myeloge-
nous leukemia, chronic lymphocytic leukemia, follicular lymphoma,
and Hodgkin's lymphoma (Supplementary Tables S2.4 and S2.6),
which do not represent all forms of leukemia and lymphoma. This also
applies to the skin cancer studies, sincemost of the GWAS of skin cancer
were performed for themost frequent skin cancer subtypes, such as cu-
taneous melanoma, basal cell carcinoma, and squamous cell carcinoma.
An interesting result of the present study is the ﬁnding for the
8q24.21 region. This contains a key susceptibility locus for NSCL/P, and
although it was initially identiﬁed in a small GWAS, the genetic effect
was very pronounced [5]. The ﬁnding has since been conﬁrmed in nu-
merous GWAS and targeted replication studies [42]. The top marker,
rs987525, maps to an intergenic region, which may contain remote
cis-acting enhancers that control expression of the well known proto-
oncogene Myc in the developing murine facial prominences [64]. Six-
teen of the present cancer-risk SNPs are located in the 8q24.21 region
(Table 4). However, none of these SNPs showed a statistically signiﬁcant
association in the NSCL/P data-sets. Furthermore, none of these cancer
risk variants is in linkage disequilibriumwith rs987525, which suggests
that this locusmight contain distinct regulatory regions that are respon-
sible for different developmental processes. This hypothesis is support-
ed by data from Uslu et al. [64], who showed that a distinct region
adjacent to rs987525 contained a speciﬁc facial enhancer element. Dele-
tion of this medial-nasal enhancer resulted in a pronounced reductionin myc expression in the facial tissues of homozygous murine embryos
but not in other embryonic tissues. Therefore it is possible that the
8q24 region contains enhancers that control the expression of Myc in
either facial development or cancer but not in both.
In summary, the present study is the ﬁrst to characterize possible
pleiotropic risk loci for NSCL/P and cancer using large genome-wide
datasets. Suggestive evidence for a common genetic background was
found for NSCL/P and follicular lymphoma at 6p21.33, and for NSCL/P
and squamous cell carcinoma of the skin at 20q12. Whether, and to
what extent, the development of these phenotypes is inﬂuenced by an
altered function of the putative candidate genes OCT4 and MAFB at
these loci remains unclear. No marker in the present study showed
pronounced effects on both phenotypes. Although inconclusive at the
single marker level, the present data represent a starting point for fur-
ther research into the common genetic etiology of OFC and cancer.
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